AI-Generated Synthetic Health Data — What Pharma Teams Need to Know

The objection arrives reliably in every meeting where synthetic health data is proposed for the first time: “But isn’t it just made-up data?”

It is a reasonable question from someone who has spent their career treating data quality as sacrosanct. It is also, in almost every technically meaningful sense, the wrong question. AI-generated synthetic health data is not invented from nothing. It is a statistically learned reflection of real patient populations — one that encodes genuine epidemiological structure without containing a single real patient’s record. Understanding this distinction is the entry point for every productive conversation about where synthetic data belongs in a pharmaceutical organisation’s analytical toolkit.

This post covers the key findings from our full technical guide — AI-Generated Synthetic Health Data: What Pharma Teams Need to Know — mapping precisely where synthetic data healthcare applications work and where they don’t, the use cases where synthetic data genuinely outperforms real-world access, the cases where it does not, and — critically — where the regulatory acceptance ceiling currently sits.

---

What AI-Generated Synthetic Health Data Actually Is

A high-fidelity synthetic medical dataset is produced by a generative model — typically a Generative Adversarial Network (GAN) or Variational Autoencoder (VAE) — trained on real patient records. The model learns the statistical distributions, clinical co-occurrence patterns, temporal sequences, and demographic correlations that characterise the source population. It then generates entirely new records that reflect those learned patterns.

The output contains no real patient’s information. It is not anonymised or de-identified real data — it is statistically faithful synthetic data generated from a learned model. The privacy protection is structural: there is no real record to re-identify because no real record was included in the output.

This matters because traditional de-identification approaches operate on a continuum: the more identifying information you remove, the more analytical utility you destroy. Synthetic data generation sidesteps this trade-off entirely.

---

The Generation Landscape: Not All Methods Are Equal

The choice of generation architecture determines the fidelity, privacy guarantees, and fitness-for-purpose of the output. The four principal methods in current use are:

Statistical sampling — the simplest synthetic data generation healthcare teams can deploy — fits parametric distributions to the training data and samples from the fitted model. Fast and simple; limited fidelity for complex clinical relationships.

GANs (Generative Adversarial Networks) use adversarial training between a generator and discriminator network. The current gold standard for high-fidelity synthetic EHR and claims data generation — but require careful architecture selection for healthcare’s temporal data structures.

VAEs (Variational Autoencoders) encode real data to a latent space and decode samples from it. Particularly effective for continuous biomarker data and genomics.

Diffusion models have recently demonstrated state-of-the-art fidelity for medical imaging synthesis and are beginning to be applied to tabular EHR data. The most technically demanding but potentially the highest-fidelity option for complex structured data.

For longitudinal EHR data specifically, architecture selection is critical. Standard image-generation GANs do not preserve temporal patient trajectories. Healthcare-specific architectures — medGAN, RGAN, and transformer-based variants — are required to capture the sequential clinical dependencies that make longitudinal synthetic data analytically useful.

---

Differential Privacy: The Mathematical Guarantee That Changes the Conversation

The rigorous answer to “how private is this?” is not a vendor’s marketing claim — it is a mathematical parameter called epsilon (ε).

Differential privacy provides a formal bound on the maximum information leakage about any individual in the training dataset. Implemented via Differentially Private Stochastic Gradient Descent (DP-SGD) during GAN training, it clips per-example gradient contributions and adds calibrated noise before model updates — ensuring that the presence or absence of any individual record has bounded influence on the trained model’s outputs.

The privacy budget ε quantifies this guarantee. Values at or below 1 provide strong protection but degrade statistical fidelity. Values between 1 and 5 represent the practical range for most healthcare applications. Values above 10 provide limited meaningful protection and should generally not be presented as privacy-preserving.

The critical point for pharma teams: ε selection requires a formal privacy impact assessment, and the rationale must be documented. This is not a technical parameter to be set by the data vendor without organisational input.

---

Validation: The Three Dimensions That Cannot Be Skipped

A synthetic dataset that has not been rigorously validated is analytically worthless and potentially misleading. Validation requires three independent assessments:

Statistical fidelity — do the synthetic data’s distributions, pairwise correlations, and multivariate dependencies match the real data? Key metrics: Jensen-Shannon divergence per variable (target < 0.05); mean absolute pairwise correlation difference (target < 0.10); discriminator AUC from a trained classifier (target < 0.60).

Analytical utility — does a model trained on synthetic data and tested on real data perform comparably to a model trained on real data? The Train on Synthetic, Test on Real (TSTR) paradigm quantifies this gap. For RWE applications, additionally validate that regression coefficients and hazard ratios estimated on synthetic data are within pre-specified equivalence margins of those from real data.

Privacy — do adversarial membership inference attacks, attribute inference tests, and nearest-neighbour distance analyses confirm that no real record can be recovered from the synthetic dataset? Theoretical DP guarantees must be confirmed empirically.

Validation is also use-case specific. A synthetic dataset validated for ML model training is not automatically validated for survival analysis or causal effect estimation.

---

Where Synthetic Data Genuinely Outperforms Real-World Access

Rare disease data augmentation. For conditions affecting fewer than 1 in 2,000 people, real-world datasets are structurally inadequate for many analytical tasks. Conditional GAN-based minority-class oversampling can augment rare disease cohorts in ways that improve ML model stability, subgroup analysis power, and treatment pattern characterisation — with validated clinical plausibility.

Cross-border GDPR compliance. Patient-level data from national health systems cannot be freely exported under GDPR and national health data legislation. Synthetic data generated at each national site — containing no real patient records — can be legally combined across borders, enabling true multi-country data integration without triggering data transfer restrictions. This is currently one of the most compelling practical use cases for synthetic data in healthcare in European pharma.

ML training pipelines. AI-based clinical decision support tools require large, diverse, labelled datasets. Synthetic data can be scaled to arbitrary size, generated with controlled demographic distributions for bias testing, and produced with known ground-truth labels for supervised learning tasks. This is the leading application of synthetic data in machine learning for medicine and healthcare.

Analytical pipeline development and testing. Synthetic data allows full end-to-end testing of analytical code, statistical models, and data processing pipelines without requiring access to real patient data during development — accelerating timelines and reducing data access burden.

---

Where Synthetic Data Falls Short

Primary causal inference. A generative model trained on observational data reproduces the statistical associations present in that data — including confounding, selection bias, and indication bias. Synthetic data does not remove these biases. It faithfully reproduces them. Causal inference from synthetic observational data inherits every methodological challenge of causal inference from real observational data, plus additional uncertainty from the generation process.

Rare safety signal detection. Adverse events occurring at 1 in 10,000 or lower rates may be structurally absent from a synthetic dataset even when present in the training data. GAN mode collapse disproportionately affects rare events. Synthetic data is currently unsuitable as the primary data source for pharmacovigilance applications.

Absolute event rate estimation. Synthetic data tends to preserve relative patterns (treatment A has higher risk than B) more reliably than absolute values (the absolute 5-year event rate is X%). Health economic modelling inputs requiring precise absolute estimates should not rely on synthetic data without specific absolute-value validation.

---

The Regulatory Acceptance Ceiling — Precisely Stated

As of 2025, no major regulatory agency permits AI-generated synthetic health data as the primary evidence source for a regulatory submission. The current consensus across FDA, EMA, and MHRA is that synthetic data may support, supplement, or augment real-world evidence — not substitute for it.

The FDA’s most advanced acceptance is in the medical device pathway, where CDRH explicitly permits synthetic data as training and testing data for AI/ML-based medical devices. For drug development, synthetic data is accepted for trial simulation, sensitivity analysis augmentation, and exploratory rare disease contexts — but not as primary safety or efficacy evidence.

The ceiling is not static. The EMA’s DARWIN EU programme is actively piloting synthetic data for cross-border research. FDA engagement with synthetic control arm approaches in rare disease is ongoing. Organisations that build the validation infrastructure and regulatory documentation practices now will be better positioned as guidance evolves.

When synthetic data is included in any regulatory submission, even as supplementary material, regulators expect explicit documentation of: generation methodology and DP parameters; validation evidence with pre-specified acceptance thresholds; the specific analytical purpose; limitation acknowledgements; and real-data comparability evidence where available.

---

What Pharma Teams Should Do Now

The practical entry point for most pharmaceutical organisations is not a large-scale synthetic data programme — it is a bounded pilot in a use case that is clearly in the appropriate zone and that builds the internal validation and governance infrastructure on which broader deployment depends.

The most immediately accessible starting points are: using open-source frameworks (SDV, CTGAN) or commercial synthetic healthcare data platforms (Gretel.ai, Syntegra, MDClone) for ML pipeline development and testing; applying synthetic data augmentation to a rare disease cohort where real-world data limitations are actively constraining analysis; and establishing an internal governance policy that defines approved and prohibited uses before any cross-organisational deployment.

The “made-up data” objection will come up again. The answer — grounded in GAN architecture, differential privacy mathematics, and three-dimension validation methodology — is precisely stated in the full guide.

---

---

MEDDDICAL is a Pan-European Real-World Evidence advisory firm helping pharmaceutical and MedTech organisations navigate the real-world data landscape. For expert guidance on synthetic data strategy, vendor evaluation, and validation framework design, contact us.